Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 inhalation safety and pharmacokinetic study of DS-2319b in healthy Japanese men
jRCT2051200153Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of nafamostat mesilate in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Safety. Started Mar 2021; status: completed.
02
Drugs
nafamostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051200153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200153.